CAR-T for ERBB2 cancer cell targeting may be used to complement other treatment modalities such as immune checkpoint inhibitors [63], oncolytic virus [64], and nanoparticles [65], or even with other types of immune effector cells, such as natural killer cells [66]. The gene discussed is ERBB2; the disease is cancer.